Keyword: Sarepta Therapeutics
Sarepta has been signing a series of new R&D pacts since its controversial DMD drug approval last fall, and today it’s penned a deal for one of the hottest research areas around: CRISPR.
Catabasis is looking to test its experimental Duchenne drug edasalonexent in a late-stage trial.
Allergan CFO Hilado and Gilead COO Young will retire from their positions and Rubius has poached a GSK SVP as CMO.
The startup has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million to take a LANCL2-targeted IBD drug into the clinic.
Sarepta CEO Doug Ingram aims to raise $250 million in a public stock offering as the company looks beyond its first product, DMD therapy Exondys 51.
Sarepta offers Exondys 51 outside of the U.S. through a managed access program run by Clinigen, as an EMA decision is expected next year.
Doug Ingram has become the latest person to take a turn as Sarepta Therapeutics CEO.
Sarepta Therapeutics has penned its second DMD gene therapy pact this year.
Ed Kaye, who did what looked impossible a year ago and got Sarepta’s controversial Duchenne med approved, will step down later this year.
Sanofi Genzyme's CEO Meeker will step down amid key rollouts, Allergan's chief strategy officer Patel became CEO at startup Relay, and more.